Entrada Therapeutics (TRDA) EBITDA Margin (2023 - 2026)
Entrada Therapeutics (TRDA) recorded quarterly EBITDA Margin of 4585.49% in Q1 2026, down 52.21% quarter-over-quarter from 3012.55% in Q4 2025, and down 450343.0% on a YoY basis from N/an in Q1 2025.
Entrada Therapeutics (TRDA) EBITDA Margin (2023 - 2026) Analysis & Trends
Entrada Therapeutics' EBITDA Margin history runs 4 years deep, the most recent figure standing at 4585.49% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 450343.0% year-over-year to 4585.49%; the TTM figure through Mar 2026 stood at 2898.38% (down 291316.0% YoY), while the FY2025 annual figure was 562.74%, down 59377.0% from the prior year.
- EBITDA Margin was 4585.49% for Q1 2026 at Entrada Therapeutics, down from 3012.55% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 82.25% in Q3 2023 to a low of 4585.49% in Q1 2026.
- Historically, EBITDA Margin has averaged 975.79% across 4 years, with a median of 65.05% in 2024.
- The sharpest annual moves came in 2024 and 2026: EBITDA Margin surged 20272 bps in 2024, then plunged 450343 bps in 2026.
- A 4-year view of EBITDA Margin shows it stood at 21.16% in 2023, then jumped by 101 bps to 0.31% in 2024, then plunged by 971335 bps to 3012.55% in 2025, then sank by 52 bps to 4585.49% in 2026.
- The last three EBITDA Margin figures came in at 4585.49% (Q1 2026), 3012.55% (Q4 2025), and 2720.76% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Entrada Therapeutics | 295.36 Mn | 295.36 Mn | - | -4,585.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,585.49% |
| Dec 31, 2025 | -3,012.55% |
| Sep 30, 2025 | -2,720.76% |
| Jun 30, 2025 | -2,212.31% |
| Mar 31, 2025 | -82.06% |
| Dec 31, 2024 | 0.31% |
| Sep 30, 2024 | -65.05% |
| Jun 30, 2024 | 58.03% |
| Mar 31, 2024 | 39.00% |
| Dec 31, 2023 | -21.16% |
| Sep 30, 2023 | 82.25% |
| Jun 30, 2023 | -144.69% |
| Mar 31, 2023 | -20.82% |